Express Pharma
Home  »  Latest Updates  »  Lupin receives EIR from US FDA

Lupin receives EIR from US FDA


The company’s Aurangabad facility underwent inspection in April 2017

Lupin has received notification that the inspection carried out by the US FDA in April 2017 at its Aurangabad facility is now closed and the agency has issued an Establishment Inspection Report (EIR). This closes all outstanding US FDA inspections at Lupin’s Aurangabad facility.

Comments are closed.